Natural compounds produced by the world's microbes were once the go-to source of molecules for the drug industry before the chemistry dried up and big pharma went packing. Now, researchers hope that advances in genomics will bring companies back into the fold. Daniel Grushkin visits one startup hoping to accelerate the process.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grushkin, D. Natural products emergent. Nat Med 19, 390–392 (2013). https://doi.org/10.1038/nm0413-390
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0413-390
This article is cited by
-
Juno's whopping $120 million success signals new investing style
Nature Medicine (2014)
-
Antibiotics in the clinical pipeline in 2013
The Journal of Antibiotics (2013)
